Milatuzumab Stocks List

Recent Signals

Date Stock Signal Type
2019-12-06 IMMU MACD Bullish Signal Line Cross Bullish
2019-12-06 IMMU Expansion Breakout Bullish Swing Setup
2019-12-06 IMMU New 52 Week Closing High Bullish
2019-12-06 IMMU Wide Range Bar Range Expansion
2019-12-06 IMMU New 52 Week High Strength
2019-12-06 STRO Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2019-12-06 STRO Crossed Above 50 DMA Bullish

Milatuzumab (or hLL1) is an anti-CD74 humanized monoclonal antibody for the treatment of multiple myeloma non-Hodgkin’s lymphoma and chronic lymphocytic leukemia.The drug is the first anti-CD74 antibody that has entered into human testing and is currently being studied for the treatment of multiple myeloma. Milatuzumab has received orphan drug designation from the Food and Drug Administration in the United States for the treatment of multiple myeloma and chronic lymphocytic leukemia.
Milatuzumab was developed by Immunomedics, Inc, (Morris Plains NJ USA).

More about Milatuzumab